What Was On Hold Is New Again As Impact Raises $22.5m For Fedratinib
Medicxi-funded Impact Biomedicines gave Sanofi a stake in the start-up to acquire fedratinib and bring the JAK2 inhibitor, which was placed on a clinical hold in 2013, to patients who are out of options.
You may also be interested in...
BMS Buoyed By EU Approval Of Myelofibrosis Drug
There have been lots of twists and turns on the development path for Inrebic which is now the second JAK inhibitor to be approved in the EU for MF since the blockbuster Jakavi was cleared in 2012.
Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
John Hood spent the past few years looking for a drug candidate worth forming a new company around before he zeroed in on Lilly’s taladegib as a treatment for idiopathic pulmonary fibrosis.
Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol
Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.